|Project Title||Principal Investigator||Institution|
|Aberrant synaptic function due to TSC mutation in autism||Sulzer, David||Columbia University Medical Center|
|A better understanding of the therapeutic actions of specific neuroleptics in autism||Greengard, Paul||The Rockefeller University|
|A mouse knock-in model for Engrailed 2 autism susceptibility||Millonig, James||University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School|
|Analysis of 15q11-13 GABA-A receptor defects in autism||Hogart, Amber||University of California, Davis|
|Analysis of FGF17 roles and regulation in mammalian forebrain development||Hoch, Renee||University of California, San Francisco|
|Animal models of neuropsychiatric disorders||Crawley, Jacqueline||National Institutes of Health|
|A non-human primate autism model based on maternal infection||Patterson, Paul||California Institute of Technology|
|Cellular and molecular alterations in gabaergic inhibitory circuits by mutations in MECP2, a gene implicated in the Rett syndrome of the autism spectrum disorders||Huang, Z. Josh||Cold Spring Harbor Laboratory|
|Cognitive mechanisms of serially organized behavior||Terrace, Herbert||Columbia University|
|Connectopathic analysis of autism||Sanes, Joshua||Harvard University|
|Distinct function of the neuroligin 3 postsynaptic adhesion complex||Budreck, Elaine||Columbia University|
|Dysregulation of p13/AKT in mouse models for social interaction deficits and for ASD with macrocephaly||Parada, Luis||University of Texas Southwestern Medical Center|
|Exploring the role of synaptic proteins in mouse models of autism||Heintz, Nathaniel||The Rockefeller University|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Generation of genetic models of autism in mice||Fishell, Gordon||New York University School of Medicine|
|Genetic analyses of ARX homeobox gene function in neurodevelopmental disorders||Sengupta, Piali||Brandeis University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Investigation of the role of MET kinase in autism||Dawson, Ted||Johns Hopkins University School of Medicine|
|Mice lacking Shank postsynaptic scaffolds as an animal model of autism||Sheng, Morgan||Massachusetts Institute of Technology|
|Models and mechanisms - 1||Sur, Mriganka||Massachusetts Institute of Technology|
|Models and mechanisms - 2||Sahin, Mustafa||Boston Children's Hospital|
|Molecular determinants of L-type calcium channel gating||Colecraft, Henry||Columbia University|
|Neocortical regionalization: Analysis of genetic and epigenetic influences||Huffman, Kelly||University of California, Riverside|
|Neural and cognitive mechanisms of autism||Sur, Mriganka||Massachusetts Institute of Technology|
|Neurexin-neuroligin trans-syanptic interaction in learning and memory||Kandel, Eric||Columbia University|
|IACC Strategic Plan Objectives||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built.Â The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.